Application of decellularized vascular matrix in small-diameter vascular grafts

Coronary artery bypass grafting (CABG) remains the most common procedure used in cardiovascular surgery for the treatment of severe coronary atherosclerotic heart disease. In coronary artery bypass grafting, small-diameter vascular grafts can potentially replace the vessels of the patient. The compl...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in bioengineering and biotechnology Vol. 10; p. 1081233
Main Authors Li, Yuanming, Zhou, Ying, Qiao, Weihua, Shi, Jiawei, Qiu, Xuefeng, Dong, Nianguo
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 06.01.2023
Subjects
Online AccessGet full text
ISSN2296-4185
2296-4185
DOI10.3389/fbioe.2022.1081233

Cover

Loading…
More Information
Summary:Coronary artery bypass grafting (CABG) remains the most common procedure used in cardiovascular surgery for the treatment of severe coronary atherosclerotic heart disease. In coronary artery bypass grafting, small-diameter vascular grafts can potentially replace the vessels of the patient. The complete retention of the extracellular matrix, superior biocompatibility, and non-immunogenicity of the decellularized vascular matrix are unique advantages of small-diameter tissue-engineered vascular grafts. However, after vascular implantation, the decellularized vascular matrix is also subject to thrombosis and neoplastic endothelial hyperplasia, the two major problems that hinder its clinical application. The keys to improving the long-term patency of the decellularized matrix as vascular grafts include facilitating early endothelialization and avoiding intravascular thrombosis. This review article sequentially introduces six aspects of the decellularized vascular matrix as follows: design criteria of vascular grafts, components of the decellularized vascular matrix, the changing sources of the decellularized vascular matrix, the advantages and shortcomings of decellularization technologies, modification methods and the commercialization progress as well as the application prospects in small-diameter vascular grafts.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Jangwook P. Jung, Louisiana State University, United States
Marie-Noelle Giraud, Université de Fribourg, Switzerland
Filippo Naso, Biocompatibility Innovation Srl, Italy
Edited by: Luanda Lins, University of Twente, Netherlands
This article was submitted to Tissue Engineering and Regenerative Medicine, a section of the journal Frontiers in Bioengineering and Biotechnology
ISSN:2296-4185
2296-4185
DOI:10.3389/fbioe.2022.1081233